Plaquenil is the brand name for the antimalarial drug hydroxychloroquine used in several inflammatory conditions. Its primary therapeutic use is to modulate immune responses in diseases such as rheumatoid arthritis and systemic lupus erythematosus. The medication functions by interfering with the processing of autophagy in cells, leading to reduced antigen presentation. By limiting the transport of toxic substances from lysosomes to the cytosol, it decreases inflammatory cytokine production. This inhibition also disrupts the acidic environment required for certain pathogens, contributing to its antimalarial effect. Overall, the drug exerts its effects through alteration of intracellular signaling pathways that regulate inflammation. Pharmacokinetics involve oral absorption followed by distribution to target tissues where it accumulates. The cumulative result is a controlled immune response that helps manage chronic autoimmune symptoms.

Plaquenil is the brand name for the antimalarial drug chloroquine, used primarily to treat and prevent malaria infections. It is also prescribed for autoimmune conditions such as rheumatoid arthritis and systemic lupus erythematosus due to its anti-inflammatory and immunomodulatory effects. The drug functions by accumulating in lysosomes and raising their ph, which disrupts processes that depend on acidic cellular compartments. This ph alteration interferes with the trafficking and activity of proteins involved in antigen presentation and parasite replication. By modulating these pathways, Plaquenil reduces immune cell activation in autoimmune disease and impairs the survival of malaria parasites within red blood cells. The overall result is a decreased spread of infection and a mitigation of autoimmune tissue damage.

Plaquenil may cause gastrointestinal discomfort such as nausea and diarrhea. Some patients experience skin reactions like rash or itching. Rarely, visual disturbances including blurred vision can occur. Prolonged use has been linked to rare heart rhythm abnormalities. The medication can affect blood cell counts leading to anemia or low white blood cell counts. Neurological symptoms such as headache or dizziness are possible. Liver enzyme elevations may be observed during routine monitoring. Allergic reactions manifesting as swelling or breathing difficulty can develop in susceptible individuals.

Plaquenil may cause gastrointestinal discomfort such as nausea or diarrhea. Some patients experience headaches or dizziness during treatment. Skin reactions including rash or itching can occur. Visual disturbances such as blurred vision have been reported. Rarely the medication may affect heart rhythm leading to arrhythmias. Long term use requires monitoring of blood counts and kidney function.